Plasma biomarker signature associated with improved survival in advanced non-small cell lung cancer patients on linifanib.

Abstract

OBJECTIVES:

Linifanib, a potent and selective inhibitor of the tyrosine kinase activity of vascular endothelial growth factor and platelet-derived growth factor receptors, has clinical activity in advanced non-small cell lung cancer (NSCLC) both as monotherapy in the relapsed setting or with carboplatin and paclitaxel in the first-line setting. Though benefit was observed in unselected patient populations, identification of predictive biomarkers is critical for further development of this novel agent.

MATERIALS AND METHODS:

Data from 4 randomized studies in relapsed NSCLC with linifanib (n=116) or other treatments (n=125) were examined in an exploratory analysis to identify a biomarker profile predictive of favorable survival.

RESULTS:

A signature combining the established tumor markers carcinoembryonic antigen (CEA) and cytokeratin 19 fragments (CYFRA 21-1) was predictive of a favorable outcome. This signature was associated with improved survival in patients receiving linifanib monotherapy (hazard ratio [HR]=0.51 vs signature negative; p=0.002), but not in those receiving other anti-cancer treatments (p=0.716). This signature was validated on baseline plasma samples from patients enrolled in a randomized trial of daily linifanib 7.5 mg, linifanib 12.5 mg, or placebo added to first-line carboplatin and paclitaxel chemotherapy for advanced, nonsquamous NSCLC. Only linifanib-treated signature-positive patients had significant improvement in progression-free survival (PFS). Median PFS with placebo was 5.2 months versus 10.2 months (HR=0.49, p=0.049) for those receiving linifanib 7.5mg, and 8.3 months (HR=0.38, p=0.029) for linifanib 12.5 mg. Overall survival for signature-positive patients was 11.3 months with placebo, 12.5 months with linifanib 7.5mg (HR=1.02, p=0.758), and 17.4 months with linifanib 12.5 mg (HR=0.54, p=0.137).

CONCLUSION:

This baseline plasma biomarker signature is associated with improved outcome in advanced NSCLC patients receiving linifanib. Utility of the biomarker signature in patient selection for linifanib therapy in NSCLC merits evaluation in larger, prospective trials that are powered to detect a survival benefit.

• Authors: Evelyn M McKeegan, Peter J Ansell, Gerard Davis, Sabrina Chan, Raj K Chandran, Susan H Gawel, Barry L Dowell, Anahita Bhathena, Arunava Chakravartty, Mark D McKee, Justin L Ricker, Dawn M Carlson, Suresh S Ramalingam, Viswanath Devanarayan
• Journal: Lung cancer (Amsterdam, Netherlands) (Lung Cancer) Vol. 90 Issue 2 Pg. 296-301 (Nov 2015) ISSN: 1872-8332 [Electronic] Ireland
• PMID: 26424209 (Publication Type: Journal Article, Research Support, Non-U.S. Gov't)
• Copyright: Copyright © 2015. Published by Elsevier Ireland Ltd.

Chemical References

• Antigens, Neoplasm
• Biomarkers, Tumor
• Carcinoembryonic Antigen
• Indazoles
• Keratin-19
• Phenylurea Compounds
• antigen CYFRA21.1
• Carboplatin
• linifanib
• Paclitaxel

Topics

• Antigens, Neoplasm (metabolism)
• Antineoplastic Combined Chemotherapy Protocols (therapeutic use)
• Biomarkers, Tumor (blood)
• Carboplatin (administration & dosage)
• Carcinoembryonic Antigen (metabolism)
• Carcinoma, Non-Small-Cell Lung (blood, drug therapy, mortality, pathology)
• Disease-Free Survival
• Female
• Humans
• Indazoles (administration & dosage)
• Keratin-19 (metabolism)
• Lung Neoplasms (blood, drug therapy, mortality, pathology)
• Male
• Middle Aged
• Paclitaxel (administration & dosage)
• Phenylurea Compounds (administration & dosage)